863491-70-7

Usage

Uses

Used in Pharmaceutical Industry:
C₄₂H₃₇FN₄O₄ is used as an antidepressant medication for the treatment of depression, panic disorder, and other mood disorders. Its ability to selectively inhibit the reuptake of serotonin in the brain helps to increase the availability of serotonin, thereby alleviating depressive and anxiety symptoms.
Used in Mental Health Treatment:
Fluoxetine is utilized as a mood stabilizer in the management of various mental health conditions, including obsessive-compulsive disorder, bulimia nervosa, and premenstrual dysphoric disorder. Its regulatory effect on serotonin levels contributes to the mitigation of mood swings and emotional instability associated with these conditions.
Used in Veterinary Medicine:
C₄₂H₃₇FN₄O₄ is also employed in veterinary medicine for the treatment of behavioral disorders and anxiety in animals, such as separation anxiety in dogs and excessive grooming in cats. Its efficacy in modulating serotonin levels makes it a valuable tool in improving the emotional well-being of pets.

Upstream product

• 10349-57-2 Quinoline-6-carboxylic acid 
• 863492-33-5 quinoline-6-carboxylic acid benzyl Ester 
• 863492-35-7 2-amino-quinoline-6-carboxylic acid benzyl ester 
• 140-75-0 para-fluorobenzylamine 
• 84174-25-4 p-fluorobenzylamine formamide 
• 405-66-3 (4-Fluoro-benzyl)-methyl-amine 

Downstream Products

• 1356917-05-9 C₄₃H₃₉FN₄O₅ 

Relevant academic research and scientific papers

Discovery of microsomal triglyceride transfer protein (MTP) inhibitors with potential for decreased active metabolite load compared to dirlotapide

Analogues related to dirlotapide (1), a gut-selective inhibitor of microsomal triglyceride transfer protein (MTP) were prepared with the goal of further reducing the potential for unwanted liver MTP inhibition and associated side-effects. Compounds were designed to decrease active metabolite load: reducing MTP activity of likely human metabolites and increasing metabolite clearance to reduce exposure. Introduction of 4′-alkyl and 4′-alkoxy substituents afforded compounds exhibiting improved therapeutic index in rats with respect to liver triglyceride accumulation and enzyme elevation. Likely human metabolites of select compounds were prepared and characterized for their potential to inhibit MTP in vivo. Based on preclinical efficacy and safety data and its potential for producing short-lived, weakly active metabolites, compound 13 (PF-02575799) advanced into phase 1 clinical studies.

SUBSTITUTED QUINOLINE COMPOUNDS

This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R1-R7, X1, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.